![Deepak Gondaliya](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Deepak Gondaliya
Corporate Officer/Principal presso Emcure Pharmaceuticals Ltd.
Posizioni attive di Deepak Gondaliya
Società | Posizione | Inizio | Fine |
---|---|---|---|
Emcure Pharmaceuticals Ltd.
![]() Emcure Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India. | Corporate Officer/Principal | 01/07/2013 | - |
Storia della carriera di Deepak Gondaliya
Precedenti posizioni note di Deepak Gondaliya
Società | Posizione | Inizio | Fine |
---|---|---|---|
SUN PHARMACEUTICAL INDUSTRIES LTD. | Corporate Officer/Principal | - | - |
Formazione di Deepak Gondaliya
Hemchandracharya North Gujarat University | Doctorate Degree |
Statistiche
Distribuzione geografica
India | 4 |
Posizioni
Corporate Officer/Principal | 2 |
Doctorate Degree | 1 |
Settori
Health Technology | 3 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
SUN PHARMACEUTICAL INDUSTRIES LTD. | Health Technology |
Aziende private | 1 |
---|---|
Emcure Pharmaceuticals Ltd.
![]() Emcure Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India. | Health Technology |
- Borsa valori
- Insiders
- Deepak Gondaliya
- Esperienza